SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Polls open in tense Uganda election amid widespread delays - 2Top Breakfast Food: What's Your Morning Enjoyment?
- 3Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- 4Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- 5Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- Delta flight bound for Atlanta makes emergency landing after engine issue
- The Response to Self-improvement: Embracing a Development Outlook
- Going with Children: Tips for Tranquil Family Get-aways
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
